Gene Therapy Approaches to Replace or Restore Dystrophin PF-06939926 – Kasia Lobello, MD (Pfizer, Inc.) RGX-202 – Jahannaz Dastgir, DO (REGENXBIO) scAAV9.U7-ACCA – Kevin Flanigan, MD (Nationwide Children’s Hospital) SGT-001 – Carl Morris, PhD (Solid Biosciences) SRP-9001 – Teji Singh, MD (Sarepta Therapeutics) 3 years ago 2022 PPMD Annual Conference,Conferences & Meetings You may also like 11:20 PTC Therapeutics (Ataluren) 5 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 15:10 Daiichi-Sankyo 5 years ago Conferences & Meetings,In the Pipeline: Restoring Dystrophin 20:43 ReveraGen BioPharma 5 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 12:20 Catabasis 5 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 11:23 Antisense Therapeutics 5 years ago Conferences & Meetings,In the Pipeline: Reducing Inflammation 13:19 PTC Therapeutics 5 years ago Approved Therapies,Conferences & Meetings 15:43 Sarepta Therapeutics 5 years ago Approved Therapies,Conferences & Meetings 7:48 What is a Post Market Study? 5 years ago Approved Therapies,Conferences & Meetings «1…2223242526…28»Page 24 of 28